InvestorsHub Logo
Followers 0
Posts 918
Boards Moderated 0
Alias Born 11/11/2017

Re: None

Monday, 02/01/2021 8:25:35 AM

Monday, February 01, 2021 8:25:35 AM

Post# of 42433
Competitor company. Much better outcomes

What are the most effective therapies for treating a SARS-CoV-2 infection? Which therapies are showing promise, and which are little more than snake oil? Keeping track of treatments is tricky, with news of new vaccines and drugs breaking almost daily.
The German government has now announced it will buy 200,000 doses of bamlanivimab and REGN-CoV-2 for a total cost of €400 million ($485 million), which works out as €2,000 ($2,400) per dose. The drugs will be administered to high-risk patients. Bamlanivimab is a single antibody therapy produced by Eli Lilly. REGN-CoV-2 consists of two antibodies — casirivimab and imdevimab — and has been developed by Regeneron.
Former US President Donald Trump was treated with the latter after contracting the coronavirus in October last year. Bamlanivimab and REGN-CoV-2 both received emergency use by the US Food and Drug Administration (FDA) in November 2020. The European Union has yet to greenlight either of the therapies.